India
· Delayed Price · Currency is INR Glenmark Pharmaceuticals Statistics
Total Valuation
Glenmark Pharmaceuticals has a market cap or net worth of INR 480.48 billion. The enterprise value is 476.19 billion.
| Market Cap | 480.48B |
| Enterprise Value | 476.19B |
Important Dates
The next estimated earnings date is Thursday, October 31, 2024.
| Earnings Date | Oct 31, 2024 |
| Ex-Dividend Date | Sep 16, 2024 |
Share Statistics
Glenmark Pharmaceuticals has 282.19 million shares outstanding. The number of shares has decreased by -0.07% in one year.
| Shares Outstanding | 282.19M |
| Shares Change (YoY) | -0.07% |
| Shares Change (QoQ) | -0.02% |
| Owned by Insiders (%) | 3.79% |
| Owned by Institutions (%) | 34.78% |
| Float | 138.14M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 31.91 |
| PS Ratio | 3.73 |
| PB Ratio | 6.12 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -36.31 |
| EV / Sales | 3.70 |
| EV / EBITDA | 20.31 |
| EV / EBIT | 29.24 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 15.69 |
| Debt / EBITDA | 0.53 |
| Debt / FCF | n/a |
| Interest Coverage | 3.67 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Capital (ROIC) | 8.65% |
| Revenue Per Employee | 8.58M |
| Profits Per Employee | -874,865 |
| Employee Count | 14,989 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +114.73% in the last 52 weeks. The beta is 0.91, so Glenmark Pharmaceuticals's price volatility has been similar to the market average.
| Beta (5Y) | 0.91 |
| 52-Week Price Change | +114.73% |
| 50-Day Moving Average | 1,486.83 |
| 200-Day Moving Average | 1,089.73 |
| Relative Strength Index (RSI) | 70.56 |
| Average Volume (20 Days) | 1,299,164 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Glenmark Pharmaceuticals had revenue of INR 128.61 billion and -13.11 billion in losses. Loss per share was -46.48.
| Revenue | 128.61B |
| Gross Profit | 85.26B |
| Operating Income | 16.29B |
| Pretax Income | 3.47B |
| Net Income | -13.11B |
| EBITDA | 23.44B |
| EBIT | 16.29B |
| Loss Per Share | -46.48 |
Balance Sheet
The company has 16.59 billion in cash and 12.31 billion in debt, giving a net cash position of 4.29 billion or 15.19 per share.
| Cash & Cash Equivalents | 16.59B |
| Total Debt | 12.31B |
| Net Cash | 4.29B |
| Net Cash Per Share | 15.19 |
| Equity (Book Value) | 78.48B |
| Book Value Per Share | 278.09 |
| Working Capital | n/a |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 66.29%, with operating and profit margins of 12.66% and -10.20%.
| Gross Margin | 66.29% |
| Operating Margin | 12.66% |
| Pretax Margin | 2.70% |
| Profit Margin | -10.20% |
| EBITDA Margin | 18.23% |
| EBIT Margin | 12.66% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 2.50, which amounts to a dividend yield of 0.15%.
| Dividend Per Share | 2.50 |
| Dividend Yield | 0.15% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.07% |
| Shareholder Yield | 0.21% |
| Earnings Yield | -2.73% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on September 10, 2007. It was a forward split with a ratio of 2.
| Last Split Date | Sep 10, 2007 |
| Split Type | Forward |
| Split Ratio | 2 |